cause of open-angle glaucoma worldwide. To better understand the etiology of XFS, we conducted a genome-wide association study (GWAS) of 1,484 cases and 1,188 controls from Japan and followed up the most significant findings in a further 6,901 cases and 20,727 controls from 17 countries across 6 continents. We discovered a genome-wide significant association between a new locus (CACNA1A rs4926244) and increased susceptibility to XFS (odds ratio (OR) = 1.16, P = 3.36 × 10 −11 ). Although we also confirmed overwhelming association at the LOXL1 locus, the key SNP marker (LOXL1 rs4886776) demonstrated allelic reversal depending on the ancestry group (Japanese: OR A allele = 9.87, P = 2.13 × 10 −217 ; non-Japanese: OR A allele = 0.49, P = 2.35 × 10 −31 ). Our findings represent the first genetic locus outside of LOXL1 surpassing genome-wide significance for XFS and provide insight into the biology and pathogenesis of the disease.
XFS is a generalized disorder of the extracellular matrix that manifests most conspicuously in the eye. The exfoliation material consists of cross-linked, amyloid-like fibrillar material and glycoproteins. Apart from in ocular tissues, this material deposits around blood vessels, particularly in association with elastic connective tissue, and can be found in other organs 1 . The accumulation of exfoliation material deposits and pigment in the trabecular meshwork can damage this tissue and impede the drainage of aqueous humor from the eye, thus resulting in elevated intraocular pressure and glaucomatous optic neuropathy. Exfoliation glaucoma is the most serious known complication of XFS 2 .
The first GWAS of XFS was reported in 2007 and successfully identified LOXL1 as a major susceptibility locus 3 . Since then, multiple studies have uniformly corroborated the association of genetic variants of LOXL1 with XFS [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . However, data from these studies showed that associated alleles for LOXL1 SNPs frequently undergo allelic reversal depending on ancestry group 22 . These findings suggest that complex genetic mechanisms are present in XFS pathogenesis and that additional susceptibility loci for XFS remain to be identified. We assembled an international, multi-institutional collaborative effort across 6 continents and 17 countries to conduct a GWAS discovery and 2-stage replication study of XFS (Online Methods, Supplementary Fig. 1 and Supplementary Table 1) . Participating subjects provided written informed consent under the oversight of all local institutional review boards in accordance with the tenets of the Declaration of Helsinki.
For the GWAS discovery stage, we genotyped 717,991 SNP markers in 1,578 Japanese subjects with XFS (cases) and 1,215 controls using the Illumina HumanOmniExpress-12 v1.0 DNA analysis BeadChip microarray. Control subjects were drawn from the same hospital where the XFS cases were first identified. A total of 1,484 cases and 1,188 controls passed quality control filters for call rate, relatedness, heterozygosity and ancestry (see the Online Methods for details on quality control) and were included for downstream association analysis. Multiple markers in strong linkage disequilibrium (LD) at the LOXL1 locus showed strong evidence of association with XFS ( Supplementary Fig. 2a ), with rs4886776 (P = 7.37 × 10 −137 ) serving as the sentinel SNP.
A total of 66 SNPs outside of LOXL1 showed evidence of association with XFS surpassing P < 1 × 10 −4 at the GWAS discovery stage. We thus designed validation assays for these 66 SNP markers, together with LOXL1 rs4886776, and genotyped them in a follow-up collection of 2,628 XFS cases and 8,947 controls drawn from 9 countries (stage 1 validation; Supplementary Table 1) . For each SNP examined, we conducted a fixed-effects meta-analysis to summarize the observations across the nine studies. One SNP marker (rs4926244) mapping within the CACNA1A gene was associated in the GWAS discovery stage at P = 5.50 × 10 −5 (OR G allele = 1.29) and was also significantly associated in the validation stage (OR G allele = 1.17, P = 4.17 × 10 −5 ). For rs4926244, meta-analysis of both the discovery and validation stages showed a genome-wide significant association (OR G allele = 1.20, P = 2.45 × 10 −8 ) (Fig. 1, Supplementary Fig. 2b and Supplementary Table 2) . Results for all 67 SNP markers from the GWAS discovery and stage 1 replication are shown in Supplementary  Table 2 . We did not observe consistent evidence of association at CNTNAP2, a locus previously reported to associate with XFS in a pooled GWAS analysis 23 , or at other previously reported candidate genes (Supplementary Table 3) .
We subjected CACNA1A rs4926244 to further technical scrutiny in a third, independent data set consisting of 4,273 XFS cases and 11,780 controls drawn from 8 additional countries (stage 2 replication; Supplementary Table 1) . The association maintained significance, consistent with the findings from the two previous stages (OR G allele = 1.13, P = 1.14 × 10 −4 ). Together, the combined discovery and 2-stage replication collections consisting of 8,385 XFS cases and 21,915 controls provided evidence for association of the minor G allele at rs4926244 with XFS (P = 3.36 × 10 −11 ). These data suggest that risk for XFS increases by approximately 1.16-fold for each copy of the minor G allele ( Fig. 1 and Supplementary Table 4) . This association appeared to be consistent, with minimal heterogeneity 3 8 8 VOLUME 47 | NUMBER 4 | APRIL 2015 Nature GeNetics l e t t e r s with stratification for Asian (OR G allele = 1.14, P = 7.46 × 10 −6 ), European (OR G allele = 1.19, P = 1.90 × 10 −6 ) or South African (OR G allele = 1.33, P = 0.11) ancestry groups (P value for heterogeneity (P het ) = 0.5, I 2 index for heterogeneity = 0%) (Fig. 1) . SNP rs4926244 resides within an intronic region near the 3′ end of CACNA1A. It is closely flanked by recombination events (Fig. 2) and is confined to its own LD block (Supplementary Fig. 3 ). We did not observe association with any genetic marker surpassing the nominal threshold of P < 0.001 outside of this region (Fig. 2) 24 . We next performed imputation for ungenotyped SNPs at the CACNA1A locus on the basis of 1000 Genomes Project cosmopolitan data using the Phase 3 release (June 2014; Online Methods) across the GWAS discovery collection. We were able to successfully impute 5,602 SNPs across the CACNA1A locus. However, subsequent association analysis using the imputed SNPs did not identify additional genetic associations that surpassed the statistical significance of rs4926244 ( Supplementary Fig. 4) . Notably, the most significant SNPs emerging from the cosmopolitan imputation analysis were intronic and all showed moderate-to-high correlation with rs4926244 (Supplementary Table 5 ). None of these correlated SNP markers were located in strong motifs for transcription factor binding sites as identified by the Encyclopedia of DNA Elements (ENCODE). They also did not tag any common nonsynonymous variants in CACNA1A (Supplementary Table 6 ). Haplotype association analysis assessing SNPs in a two-, three-or four-marker sliding window did not find evidence of an association surpassing that observed for rs4926244 (lowest haplotype P = 0.00021; Supplementary Table 7) , and we further note that all but one haplotype showing evidence of association exceeding P < 0.0005 in the GWAS data set contained SNP rs4926244 (Supplementary Table 7 ). These findings suggest that rs4926244 is likely driving the common-variant haplotype association results and that detailed fine mapping of this locus using deep resequencing may be required. Examination of a recently available large-scale expression quantitative trait locus (eQTL) mapping database indicated that the G risk allele at rs4926244 is modestly correlated with lower CACNA1A mRNA levels in peripheral blood cells (z = −3.00, P = 0.0027), suggesting that it may influence XFS risk through an effect on CACNA1A expression 25 . Further work will be needed to evaluate its effect in human ocular tissues.
Initial analysis of the LOXL1 locus in the GWAS discovery data set comprising individuals of Japanese descent demonstrated strong association at rs4886776 (OR A allele = 8.31, P = 7.37 × 10 −137 ). The strength of this association vastly exceeded that of marker rs3825942 (responsible for a p.Gly153Asp substitution encoded in exon 1 of LOXL1), which has been the most widely tested and reported SNP association before this analysis 22 . Performing the analysis after conditioning for the allele dosage at rs4886776 extinguished the signal of association for every other genetic marker within the LOXL1 locus. Conversely, conditioning the analysis for allele dosage at rs3825942 still resulted in genome-wide significant association at many of the other LOXL1 SNPs, including rs4886776 (Supplementary Table 8 ). These data suggest that, within the Japanese GWAS discovery set, the observed association at LOXL1 can be attributed to rs4886776 alone. We note that rs4886776 is in high LD with rs1048661 (r 2 = 0.98 in 1000 Genomes Project Asians), a SNP that is responsible for another nonsynonymous substitution in LOXL1 (encoding p.Arg141Leu) but that was not directly genotyped in our data set. However, we were able to successfully impute rs1048661 in our GWAS discovery data set, and we confirmed its strong association with XFS (OR T allele = 8.13, P = 1.32 × 10 −126 ). SNP rs1048661 has previously been reported to show strong association with XFS in multiple populations, although l e t t e r s the risk allele is reversed depending on which ancestry group is being studied 11, 22 . This SNP is also in LD with several other LOXL1 SNPs located in potential transcription factor binding sites (Supplementary Table 6 ) 26, 27 . SNPs rs4886776 and rs3825942 are in moderate pairwise LD (r 2 = 0.23). When we genotyped rs4886776 for the 2,628 XFS cases and 8,947 controls from stage 1 validation (Supplementary Table 1 ), we noted very strong evidence of consistent association for Japanese individuals (OR A allele = 21.7, P = 1.54 × 10 −135 ), leading to an overwhelmingly significant association in the Japanese cases and controls analyzed (OR A allele = 9.87, P = 2.13 × 10 −217 ). Strikingly, in non-Japanese populations, the direction of the association was opposite to that seen in the Japanese (OR A allele = 0.49, P = 2.35 × 10 −31 ) (Supplementary Fig. 5 ). Such a scenario echoes recently reported observations for the reversed effect of rs3825942 on XFS risk in South Africans and suggests that the genetic mechanism whereby LOXL1 exerts its effect on individual susceptibility to XFS is complex 22 . We failed to detect any evidence of statistically significant interaction between CACNA1A rs4926244 and the sentinel LOXL1 polymorphisms, suggesting that these loci affect XFS risk via distinct biological pathways.
CACNA1A encodes the α1A subunit of the type P/Q voltagedependent calcium channel. Calcium channels are responsible for the transport of calcium ions across cell membranes and have a key role in a cell's ability to generate and transmit electrical signals. Previous electron microscopy studies on human eyes with XFS showed the presence of high calcium concentrations in direct association with aggregating XFS fibrils 28 . In addition, it is well known that fibrillin uses calcium to form stable aggregates 29 . Thus, it can be hypothesized that the altered function of a calcium channel could lead to alterations in calcium concentrations that might facilitate the formation of XFS aggregates.
As there is a paucity of information on CACNA1A expression in the eye, we examined the mRNA expression profile of CACNA1A and protein expression of CACNA1A in a variety of human ocular tissues and cell lines, respectively (Supplementary Fig. 6 ). We detected CACNA1A mRNA expression in all of the ocular tissues we studied, with the exception of the optic nerve head ( Supplementary  Fig. 6a ). Expression of different CACNA1A isoforms appears to be higher in human ocular tissue-derived cells than in cells of non-ocular origin (Supplementary Fig. 6b) . We also performed immunofluorescence and immunohistochemistry analysis on adult human eyes and observed positive immunoreactivity for CACNA1A in multiple human ocular tissues (Fig. 3, and Supplementary Figs. 7 and 8) . The distribution of CACNA1A was similar in human ocular tissues from individuals with or without XFS (Fig. 3, and Supplementary  Figs. 8 and 9) . Positive staining and localization of CACNA1A in the human eye was further corroborated by immunofluorescence microscopy analysis in mouse eyes (Supplementary Fig. 10) . In human eyes, we observed positive CACNA1A immunoreactivity in the ciliary body and iris (Fig. 3) . We also found positive staining for CACNA1A in Figs. 7 and 9) . The optic nerve glia and vascular endothelial cells also showed positive immunoreactivity for CACNA1A (Supplementary Fig. 9 ). For the retina, we observed strong, diffuse CACNA1A staining in the photoreceptor inner segments, inner nuclear layer (INL) and outer nuclear layer (ONL), and nerve fiber layer (NFL) of non-XFS globes in comparison to XFS globes, where we observed focal and patchy immunostaining of the inner segments, ONL, INL and NFL. Light-microscopy comparison of the irides in XFS-affected eyes against eyes without XFS identified typical XFS findings of exfoliated material on the posterior iris and atrophic iris pigment epithelium, as well as possible atrophy of the iris dilator muscle, in XFS-affected eyes (Fig. 3) . We also performed double-immunofluorescence microscopy for CACNA1A and LOXL1 in human eyes with and without XFS and observed colocalization of CACNA1A and LOXL1 only in the epithelium of the ciliary processes. The exfoliated material in eyes with XFS showed LOXL1-positive staining with negligible CACNA1A immunoreactivity. The ciliary body and iris smooth musculature had CACNA1A-positive immunostaining but were negative for LOXL1 staining in eyes with and without XFS (Fig. 3) . This observation raises the possibility that CACNA1A and LOXL1 contribute to XFS pathology through different mechanisms at different ocular sites. In summary, we have identified a susceptibility locus for XFS mapping to CACNA1A using a three-stage GWAS study design. Further investigation of this locus is now warranted to uncover the mechanisms through which CACNA1A affects individual susceptibility to XFS. 
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Patient recruitment. Detailed information on all XFS sample collections can be found in the Supplementary Note. All cases and controls were enrolled in the study following informed consent and ethical approval from the relevant national and regional institutional review boards for each sample collection. DNA was extracted from patient blood samples using standard, well-described laboratory procedures for genetic analysis.
Genotyping. For the GWAS discovery stage, genome-wide genotyping was performed using Illumina OmniExpress BeadChips, following the manufacturer's instructions (see URLs). For validation (stage 1), genotyping was performed using the Sequenom MassARRAY platform (see URLs). For replication (stage 2), genotyping was performed using Applied Biosystems TaqMan probes (see URLs) for samples from India, Germany, Italy, China, Iran, Poland and Argentina. The Australian replication collection had GWAS genotyping for all cases and controls using Illumina genome-wide arrays, and CACNA1A rs4926244 was directly genotyped on the GWAS arrays. We performed cross-platform concordance checks and verified >99.9% concordance of genotypes for the SNP markers of interest reported here (for example, rs4926244).
Statistical analysis. Stringent quality control filters were used to remove poorly performing samples and SNP markers in both the GWAS discovery and validation phases. SNPs with call rate <95%, with minor allele frequency <1% or showing significant deviation from Hardy-Weinberg equilibrium (P value for deviation <1 × 10 −6 ) were removed from further statistical analysis. Likewise, samples with an overall genotyping success rate of less than 95% were removed from further analysis. The remaining samples were then subjected to biological relationship verification using the principle of variability in allele sharing. Identity-by-state information was derived using PLINK (see URLs). For those pairs of individuals who showed evidence of cryptic relatedness (possibly either due to duplicated or biologically related samples), we removed the sample with the lower call rate before performing principal-component analysis (PCA). PCA was undertaken to account for spurious associations resulting from ancestral differences for individual SNPs, and principalcomponent plots were generated using the R statistical program package (see URLs). For the GWAS discovery stage, all XFS cases had genetically matched controls, as visualized spatially by PCA (Supplementary Fig. 11 ). A total of 581,023 autosomal SNPs passed quality filters for call rate and minor allele frequency and were included for further analysis. Genotypes were contrasted between XFS cases and controls using logistic regression, with adjustments for the top six principal components of genetic ancestry to further minimize confounding due to cryptic population stratification. We did not observe any evidence of genomic inflation (λ GC = 1; Supplementary Fig. 12 ), suggesting that the association results were not confounded by external artifacts such as genetic mismatch between cases and controls. Crucially, we did not observe any deviation or dispersion of test statistics when patients with XFS without glaucoma were compared to patients with exfoliation glaucoma (Supplementary  Fig. 13 ). This suggests that our primary analysis approach in combining all patients with XFS into an overall case group is valid. For the GWAS discovery, validation and replication stages, analysis of association with XFS disease status was carried out using allele-based score tests (1 degree of freedom), which modeled additive effects of the minor allele on disease risk. For the GWAS discovery stage, we incorporated the top six principal components of genetic stratification into the logistic regression model while performing the analysis for association to minimize the effect of residual population stratification. As the follow-up validation (stage 1) and replication (stage 2) phases only tested a limited number of genetic markers, we were unable to adjust for population stratification in these follow-up sample collections. However, association tests were performed by site to minimize population stratification, and statistics were subsequently combined in meta-analysis as described below. All P values reported here are two-tailed.
Meta-analysis was conducted using inverse variance weights for each sample collection, calculating an overall z statistic, its corresponding P value and an accompanying OR estimate for each SNP analyzed. The meta-analysis was performed under the fixed-effects model 30 . Analysis of LD was performed using the R software package (version 2.9.0) and associated rmeta and RColorBrewer analytical packages.
Genotype imputation. Fine-scale imputation at CACNA1A was performed using all 1,484 XFS cases and 1,188 controls passing the standard GWAS quality control checks. Imputation and phasing of genotypes were carried out using IMPUTE2 (see URLs) with cosmopolitan population haplotypes based on data from 2,535 individuals from 26 distinct populations around the world obtained from the 1000 Genomes Project Phase 3 release (June 2014) for reference panel construction. Imputed genotypes were called with an impute probability threshold of 0.90, with all other genotypes classified as missing. Additional quality control filters were applied to remove SNPs with a call rate <99% should the SNP have a minor allele frequency below 5% in either cases or controls. For common SNPs with a minor allele frequency >5%, the filtering criterion was set at a call rate of <95%.
Power calculations. All statistical power calculations were performed as previously described 31 . We present these power calculations for each of the following conditions: (i) the GWAS discovery stage only; (ii) the GWAS discovery stage plus stage 1 validation; and (iii) the GWAS discovery stage plus stage 1 validation plus stage 2 replication (Supplementary Table 9 ). Expression analysis. Multiple transcript variants encoding different isoforms have been found for CACNA1A. Here we assessed the presence of either of the two major transcripts known for CACNA1A, which encode 2,506-and 2,261-residue proteins, Ca V 2.1 variants 1 and 2, respectively (Ca V 2.1_V2 and Ca V 2.1_V1; NCBI, NM_001127222.1, NP_001120694.1 and NM_001127221.1, NP_001120693.1). All of the known critical regulatory elements of the Ca V 2.1 C-terminal tail are included in both variants, but the polyQ domain is excluded from the short-tailed Ca V 2.1_V1 isoform 32 . We used five pairs of primers spread across and common to both transcripts to assess the presence of each transcript in eye tissues (Supplementary Table 10 ). CACNA1A transcript expression was assessed by semiquantitative RT-PCR using the abovementioned CACNA1A-specific primers on total RNA extracted from a variety of ocular tissues (anterior sclera, cornea, iris, trabecular meshwork, lens capsule, retina, choroid, optic nerve head and optic nerve) with TRIzol reagent (Invitrogen) in accordance with the manufacturer's protocol. First-strand cDNA synthesis was performed with the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen). Semiquantitative RT-PCR was performed according to the manufacturer's protocol with SYBR Green Master Mix (Invitrogen) using the above CACNA1A primers. RT-PCR products were separated on a 2% agarose gel and visualized by ethidium bromide staining. The ubiquitously expressed ACTB gene (encoding β-actin) was amplified using specific primers (Supplementary Table 10 ) and used as an amplification and normalizing control.
Protein blotting. Cell lines obtained from the American Type Culture Collection included a human retinal pigment epithelial cell line (APRE-19), a human cervical adenocarcinoma cell line (HeLa S), a human breast adenocarcinoma cell line (MCF-7) and a human embryonic kidney epithelial cell line (HEK293). A human nonpigmented ciliary epithelial cell line (NPCE) was a kind gift from M. Coca-Prados (Yale School of Medicine). A human trabecular meshwork cell line (HTM) was purchased from PromoCell and tested for mycoplasma. Cell lysates were obtained by lysing individual cell lines with lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1.0% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 0.2 mM NaVO 4 , 10 mM sodium fluoride, 0.4 mM EDTA and 10% glycerol). Proteins resolved by SDS-PAGE were transferred to HyBond-C Extra nitrocellulose membranes (Amersham Life Science). Membranes were blocked with 5% nonfat milk, 0.1% Tween-20 in Trisbuffered saline (20 mM Tris-HCl, pH 7.6, 150 mM NaCl) for 1 h before incubation with antibody to CACNA1A (1:1,000 dilution; ab81011, Abcam) and antibody to actin conjugated to horseradish peroxidase (HRP) (1:50,000 dilution; sc-47778, Santa Cruz Biotechnology). Blocking and blotting with antibodies were performed in 10% horse serum (Sigma-Aldrich), 0.1% Tween-20 in PBS for 1 h. Bound primary antibodies were detected by HRPconjugated secondary antibodies (GE Healthcare Biosciences), and signals were visualized with Luminata Forte Western HRP substrate (Millipore).
Immunofluorescence confocal microscopy. Immunofluorescence confocal microscopy was performed on 4-µm paraffin sections after antigen retrieval. Blocking of tissue sections was performed with blocking buffer (10% FBS, 0.1% PBS-Tween-20; 1× penicillin and streptomycin) for 1 h at room temperature. Antibodies to CACNA1A (Abcam, ab81011) and LOXL1 (Abnova, H00004016-B01P) were diluted at 1:300 with blocking buffer and incubated with samples overnight at 4 °C. Secondary anti-mouse or anti-rabbit antibodies labeled with FITC (1:300 dilution) or Cy3 (1:300 dilution) (Jackson Labs) were also diluted in blocking buffer and were incubated with samples at room temperature for 1 h followed by application of Vectashield with 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories). Coverslips were then used to overlay the sections, and slides were stored in the dark at 4 °C until viewing with an Olympus Fluoview 1000 confocal microscope (Olympus Optical).
Immunohistochemistry. A total of seven archival enucleated globes were retrieved for immunohistochemistry analysis with antibodies to CACNA1A (1:50 dilution; Abcam) and LOXL1 (1:50 dilution; Abnova). Three human eye globes from Saudi Arabia and one from Denmark with a history of advanced XFS were obtained courtesy of D.P.E. and S. Heegaard, respectively. Three additional eyes from Singapore (Singapore General Hospital-Singapore National Eye Center Ophthalmic Pathology Service, Singapore General Hospital Pathology) that were exenterated for other external pathological diagnoses that did not involve the globe were used as non-XFS controls. Immunohistochemistry analysis was performed according to our previously published protocol 33 . In brief, paraffin sections were cut at 4 µm and placed on coated slides. Immunohistochemistry was performed using Leica Bond Polymer Refine detection kit DS9800 (Leica Microsystems). Slides were heated for 20 min at 60 °C and then loaded onto the Leica Bond III autostainer for immunohistochemical staining. Staining on the autostainer consisted of dewaxing, antigen retrieval using Leica Bond ER2 solution for 20 min at 100 °C, incubation with antibody for 20 min at room temperature and staining using the Bond polymer refine kit. Polymeric alkaline phosphatase (AP) linker antibody conjugate system (Vision Biosystems) and counterstaining with hematoxylin were applied for visualization, after which slides were dehydrated and coverslips applied.
Immunofluorescence confocal microscopy in mice. C57BL/6J and B6(Cg)-Tyrc-2J/J mice were obtained from the Jackson Laboratory production facility. Mice were housed with a 14-h light/10-h dark cycle, under the same conditions as previously described 34 . All experiments were performed in compliance with the Association for Research in Vision and Ophthalmology statement for use of animals in ophthalmic and vision research and approved by the Jackson Laboratory Animal Care and Use Committee. Adult mice were deeply anesthetized and perfused with 1× PBS, and eyes were enucleated. Fresh tissue was frozen in optimal cutting temperature (OCT) compound frozen by liquid nitrogen-cooled isopentane and stored at −80 °C or eyes were fixed overnight in 4% paraformaldehyde. Fixed eyes were cryoprotected in 30% sucrose, rinsed in 1× PBS and frozen in OCT for sectioning. Eyes were cut into 12-µm sections. Primary antibodies used to stain sections included antibodies to CACNA1A (1:500 dilution; AB5152, Millipore), endomucin (EMCN; 1:500 dilution; 14-5851, eBioscience) and smooth muscle actin (ACTA2; 1:500 dilution; ab7817, Abcam). Alexa Fluor-conjugated secondary antibodies from Invitrogen (A-11029 and A-11037) were used to label primary antibodies for immunofluorescence. Sections were desiccated, washed in 1× PBS with 0.5% Triton X-100 and incubated with primary antibodies overnight. Sections were subsequently washed in 1× PBS and incubated with secondary antibodies for 60 min. DAPI was used to stain nuclei. For each experiment, at least four sections from four eyes were assessed. Microscopy was performed on the Axio Imager (Zeiss).
